Home
HelpCatalog ID MG Rflx Myasthenia Gravis Reflexive Panel
Additional Codes
CPOE: Ref Myasthenia Gravis Reflexive Panel
DOE: MG Pnl
Specimen
Gold SST tube, collect 4.0 mL blood
Centrifuge within 2 hours of collection
Serum, 2.0 mL, refrigerated
Rejection Criteria
Plasma, contaminated specimen, grossly hemolyzed specimen, severely lipemic specimen, specimen not centrifuged <2 hours from collection, specimen at room temperature >48 hours, insufficient quantity, unlabelled specimen
Interpretative Information
Approximately 85-90 percent of patients with myasthenia gravis (MG) express antibodies to the acetylcholine receptor (AChR), which can be divided into binding, blocking, and modulating antibodies. Binding antibody can activate complement and lead to loss of AChR. Blocking antibody may impair binding of acetylcholine to the receptor, leading to poor muscle contraction. Modulating antibody causes receptor endocytosis resulting in loss of AChR expression, which correlates most closely with clinical severity of disease. Approximately 10-15 percent of individuals with confirmed myasthenia gravis have no measurable binding, blocking, or modulating antibodies.
If Acetylcholine Receptor Binding Antibody result is greater than 0.4 nmol/L or Acetylcholine Receptor Blocking Antibody result is greater than 26 percent, then Acetylcholine Receptor Modulating Antibody will be added.
If Acetylcholine Receptor Binding Antibody result is less than or equal to 0.4 nmol/L, then Muscle-Specific Kinase (MuSK) Ab, IgG will be added. Additional charges apply.
Performing Lab
ARUP Laboratories
Turn-Around-Time
3-8 days
Reference Values
| Component | Interpretative Data |
|---|---|
| Acetylcholine Binding Antibody | 0.0-0.4 nmol/L: Negative |
| 0.5 nmol/L or greater: Positive | |
| Acetylcholine Blocking Antibody | 0-26% blocking: Negative |
| 27-41% blocking: Indeterminate | |
| 42% or greater blocking: Positive |